Health Professional Radio - Podcast

Dr. Gregg Sylvester, Vice President of Medical Affairs at Seqirus discusses their portfolio of influenza vaccines with the majority of doses coming from its adjuvanted and cell-based technology platforms. There is a range of options for children aged six months and older and the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older.